5 blue chip ASX 200 shares to buy in October and hold for 10 years

Let's see why these shares could be great long term options according to analysts.

| More on:
Two smiling work colleagues discuss an investment at their office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Analysts identify five ASX 200 blue-chip shares as top long-term picks due to their robust growth potential and strategic market positions.
  • These shares are involved in sectors such as gaming technology, biotechnology, property, and digital platforms, each capitalising on global trends.
  • The companies are expected to deliver sustained earnings growth, supported by strong balance sheets and strategic expansions.

The S&P/ASX 200 index has started the new quarter just shy of record highs.

But that doesn't mean there aren't any blue-chip opportunities out there for investors.

For example, five ASX 200 blue chip shares that analysts think are in the buy zone in October are listed below. Here's why they could be top long-term picks:

Aristocrat Leisure Ltd (ASX: ALL)

Gaming technology powerhouse Aristocrat Leisure has expanded successfully beyond poker machines in recent years. For example, its acquisition of NeoGames has boosted exposure to the fast-growing real money gaming and online lottery sector. With strong earnings growth expected and resilient cash flow generation, Aristocrat remains a very attractive ASX 200 blue chip share.

Bell Potter is a fan and has a buy rating and $79.00 price target on its shares.

Cochlear Ltd (ASX: COH)

Hearing implant leader Cochlear could be a great buy and hold option. Demand for its devices is rising on the back of ageing populations across the globe and broader access to hearing healthcare. With a robust balance sheet and a track record of delivering both growth and dividends, Cochlear continues to earn its place as a reliable blue-chip holding.

UBS currently rates Cochlear as a buy with a $350.00 price target.

CSL Ltd (ASX: CSL)

Biotech leader CSL has faced pressure in recent months, with investor sentiment hit by the planned spin-off of Seqirus and potential US tariffs on pharmaceutical products. Even so, major brokers remain upbeat, with price targets significantly higher than current levels. And with plasma demand growing, new therapies in the pipeline, and a heavy investment in US manufacturing to reduce risk, CSL continues to stand out as a core long-term holding. Especially while it trades near a 52-week low.

Morgans currently has a buy rating and $293.83 price target on its shares.

Goodman Group (ASX: GMG)

Property giant Goodman Group has capitalised on surging demand for logistics and data centre space. With e-commerce, cloud computing, and AI infrastructure all requiring new developments, Goodman's global pipeline positions it at the heart of these megatrends. Backed by a strong balance sheet and disciplined capital management, this ASX 200 blue chip share looks well-placed to deliver sustained growth over the next decade.

Bell Potter is bullish and has a buy rating and $40.80 price target on its shares.

REA Group Ltd (ASX: REA)

Finally, REA Group has cemented itself as the go-to digital property platform in Australia. Pricing power, growth in adjacent services, and expansion offshore have helped it sustain double-digit earnings growth. And with the housing market expected to boom as interest rates fall, the coming years look likely to be very positive.

Bell Potter is also bullish on this one. It has a buy rating and $284.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, Goodman Group, and REA Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and Goodman Group. The Motley Fool Australia has recommended CSL, Cochlear, and Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Little girl with big glasses on a laptop with a big smile on her face.
Blue Chip Shares

Top 3 ASX 200 blue-chip shares to invest in right now

Defensive earnings, scale, and long-term relevance matter more than chasing market trends.

Read more »

asx blue chip shares represented by pile of blue casino chips in front of bar graph
Blue Chip Shares

2 beaten-down ASX blue-chip tech shares I'd buy today

2 oversold ASX tech blue chips stand out as long-term opportunities after sharp sell-offs.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

The ASX blue chip shares I'd trust with my money

Do you have money to invest? Here are three blue chips you can trust.

Read more »

Increasing stack of blue chips with a rising red arrow.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

I’m backing these two businesses as appealing dividend stocks.

Read more »

Green arrow going up on stock market chart, symbolising a rising share price.
Blue Chip Shares

3 ASX 200 shares this fund manager says are buys for 2026

These stocks could be the best blue-chips to own.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Blue Chip Shares

3 ASX blue-chip shares I'd buy with $10,000 right now

These stocks are among Australia’s biggest businesses and have a good outlook.

Read more »

Happy work colleagues give each other a fist pump.
Blue Chip Shares

Where to invest $5,000 in ASX 200 shares to try and beat the market

Let's see what makes these shares potential market-beaters.

Read more »

Happy man on a supermarket trolley full of groceries with a woman standing beside him.
Blue Chip Shares

Are Woolworths shares a blue-chip buy?

Would I buy this supermarket giant's shares? Here's my verdict.

Read more »